Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies

Neuronal pentraxin II (NPTX2) is the most highly upregulated gene in the Parkinsonian substantia nigra based on our whole genome expression profiling results. We show here that it is a novel component of Lewy bodies and Lewy neurites in sporadic Parkinson’s disease (PD). NPTX2 is also known as the neuronal activity-regulated protein (Narp), which is secreted and involved in long-term neuronal plasticity. Narp further regulates AMPA receptors which have been found to mediate highly selective non-apoptotic cell death of dopaminergic neurons. NPTX2/Narp is found in close association with alpha-synuclein aggregates in both substantia nigra and cerebral cortex in PD but unlike alpha-synuclein gene expression, which is down-regulated in the Parkinsonian nigra, NPTX2 could represent a driver of the disease process. In view of its profound (>800%) upregulation and its established role in synaptic plasticity as well as dopaminergic nerve cell death, NPTX2 is a very interesting novel player which is likely to be involved in the pathway dysregulation which underlies PD

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

Objectives: The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment and safety were secondary endpoints. Methods: In total, 1509 patients with mild to moderate Alzheimer’s disease, already treated with rivastigmine transdermal patch 4.6 or 9.5 mg/24 h, were enrolled within a 2.4-month period and prospectively followed up for 2 months on an outpatient basis. The ‘Quality of Life in Alzheimer’s disease (QOL-AD): Patient and Caregiver Report’ questionnaire was used to evaluate quality of life as an effectiveness measure. Results and conclusion: A significant improvement in quality of life, as indicated by a change of 2.7 and 2.5 points in the mean patients’ and caregiver’s QOL-AD: Patient and Caregiver Report score respectively (both p < 0.001) from baseline to end of study was recorded. No serious adverse events were reported. Compliance was high, with 100% compliance reported for almost 9 out of 10 patients at study end

Mission Planning for Low Altitude Aerial Drones during Water Sampling

Mission planning for small uncrewed aerial systems (sUAS) as a platform for remote sensors goes beyond the traditional issues of selecting a sensor, flying altitude/speed, spatial resolution, and the date/time of operation. Unlike purchasing or contracting imagery collections from traditional satellite or manned airborne systems, the sUAS operator must carefully select launching, landing, and flight paths that meet both the needs of the remote sensing collection and the regulatory requirements of federal, state, and local regulations. Mission planning for aerial drones must consider temporal and geographic changes in the environment, such as local weather conditions or changing tidal height. One key aspect of aerial drone missions is the visibility of the aircraft and communication with the aircraft. In this research, a visibility model for low-altitude aerial drone operations was designed using a GIS-based framework supported by high spatial resolution LiDAR data. In the example study, the geographic positions of the visibility of an aerial drone used for water sampling at low altitudes (e.g., 2 m above ground level) were modeled at different levels of tidal height. Using geospatial data for a test-case environment at the Winyah Bay estuarine environment in South Carolina, we demonstrate the utility, challenges, and solutions for determining the visibility of a very low-altitude aerial drone used in water sampling

Mission Planning for Low Altitude Aerial Drones during Water Sampling

Mission planning for small uncrewed aerial systems (sUAS) as a platform for remote sensors goes beyond the traditional issues of selecting a sensor, flying altitude/speed, spatial resolution, and the date/time of operation. Unlike purchasing or contracting imagery collections from traditional satellite or manned airborne systems, the sUAS operator must carefully select launching, landing, and flight paths that meet both the needs of the remote sensing collection and the regulatory requirements of federal, state, and local regulations. Mission planning for aerial drones must consider temporal and geographic changes in the environment, such as local weather conditions or changing tidal height. One key aspect of aerial drone missions is the visibility of the aircraft and communication with the aircraft. In this research, a visibility model for low-altitude aerial drone operations was designed using a GIS-based framework supported by high spatial resolution LiDAR data. In the example study, the geographic positions of the visibility of an aerial drone used for water sampling at low altitudes (e.g., 2 m above ground level) were modeled at different levels of tidal height. Using geospatial data for a test-case environment at the Winyah Bay estuarine environment in South Carolina, we demonstrate the utility, challenges, and solutions for determining the visibility of a very low-altitude aerial drone used in water sampling

Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson’s disease with cognitive decline

Abstract Although the precise neuropathological substrates of cognitive decline in Parkinson’s disease (PD) remain elusive, it has long been regarded that pathology in the CA2 hippocampal subfield is characteristic of Lewy body dementias, including dementia in PD (PDD). Early non-human primate tracer studies demonstrated connections from the nucleus of the vertical limb of the diagonal band of Broca (nvlDBB, Ch2) to the hippocampus. However, the relationship between Lewy pathology of the CA2 subfield and cholinergic fibres has not been explored. Therefore, in this study, we investigated the burden of pathology in the CA2 subsector of PD cases with varying degrees of cognitive impairment and correlated this with the extent of septohippocampal cholinergic deficit. Hippocampal sections from 67 PD, 34 PD with mild cognitive impairment and 96 PDD cases were immunostained for tau and alpha-synuclein, and the respective pathology burden was assessed semi-quantitatively. In a subset of cases, the degree of CA2 cholinergic depletion was quantified using confocal microscopy and correlated with cholinergic neuronal loss in Ch2. We found that only cases with dementia have a significantly greater Lewy pathology, whereas cholinergic fibre depletion was evident in cases with mild cognitive impairment and this was significantly correlated with loss of cholinergic neurons in Ch2. In addition, multiple antigen immunofluorescence demonstrated colocalisation between cholinergic fibres and alpha-synuclein but not tau pathology. Such specific Lewy pathology targeting the cholinergic system within the CA2 subfield may contribute to the unique memory retrieval deficit seen in patients with Lewy body disorders, as distinct from the memory storage deficit seen in Alzheimer’s disease